ArticleScientific reports2025
Therapeutic potential of no-ozone cold plasma-activated saline in osteosarcoma through mitochondrial and MAPK pathway modulation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cold Atmospheric Plasma in Biomedicine and Pharmacology: Multidisciplinary Perspectives on Therapeutic Applications.ACS pharmacology & translational science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Plasma has the unique ability to trigger potent chemical reactions, making it a promising tool in biomedical applications. Recent advancements focus on low-temperature plasmas, particularly no-ozone cold plasma (NCP), which produces RONS at body-compatible temperatures. NCP has shown notable potential in inducing apoptosis in various cancer cells. This study investigated the efficacy of no-ozone cold plasma-activated saline in human osteosarcoma cell lines, and elucidated the underlying molecular mechanisms. Cells were indirectly exposed to plasma-activated media (PAM) and PAS. Cell viability was assessed using the SRB assay, while wound healing and oxidative stress were evaluated through migration, H₂O₂, and ROS assays. Immunofluorescence and Western blotting were used to analyze apoptotic markers and signaling pathways. PAS treatment significantly reduced osteosarcoma cell viability in a cell selective manner, impaired MG-63 cell migration and increased ROS levels in a time-dependent manner. Apoptotic indicators such as cytochrome c and AIF translocation, caspase-3 and PARP cleavage, Bax upregulation, and Bcl-2 downregulation were observed. Moreover, PAS modulated MAPK signaling by enhancing p38 phosphorylation and reducing ERK activity. These findings highlight PAS as a selective and noninvasive potential therapy for osteosarcoma as its selectively targets osteosarcoma cells while sparing normal cells, and triggers apoptosis through both mitochondrial dysfunction and MAPK pathway modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.